Core Viewpoint - The sudden resignation of Gao Yingying, the newly appointed secretary of the board at Ruizhi Pharmaceutical, after only 11 days in office, raises concerns about the company's internal environment and governance issues [1][3][4]. Group 1: Company Background - Ruizhi Pharmaceutical is located in Yuexiu District, Guangzhou, and primarily engages in the research and production of biological and chemical drugs [8]. - The company has experienced significant turmoil in its leadership, with multiple changes in the actual controller and chairman, leading to instability [4][6]. Group 2: Executive Changes - Since 2021, at least eight core executives, including the general manager and CFO, have resigned, impacting strategic continuity and team stability [6]. - Gao Yingying's predecessor, Xu Jian, also faced challenges, including regulatory scrutiny and early resignation due to compliance issues [7]. Group 3: Financial Performance - The company's revenue from 2019 to 2024 showed fluctuations, with figures of 13.28 billion, 14.82 billion, 16.91 billion, 13.27 billion, 11.38 billion, and 9.7 billion respectively [8]. - In the first three quarters of 2025, Ruizhi Pharmaceutical achieved a revenue of 8.17 billion, a year-on-year increase of 13.68%, while net profit reached 7.09 million, up 111.5% [8]. Group 4: Market Reaction - The stock price of Ruizhi Pharmaceutical saw a significant increase of over 100% in 2025 but began to decline after reaching a peak of 15.28 yuan per share in July, falling to around 9.48 yuan by mid-December [8].

来源：睿智医药 而高莹莹被聘任为该公司董事会秘书才仅仅11天。 此前，12月1日盘后，睿智医药发布公告称，董事会秘书许剑提交书面辞职报告，称因工作调整原因申请提前卸任。同时，经公司董事长WOO SWEELIAN提名，董事会同意聘任高莹莹女士担任公司董事会秘书。 对于高莹莹的快速上任又离任，睿智医药在公告中并未透露更多信息。就此，南都·湾财社记者尝试致函询问情况，截至发稿尚未收到回复。 来源：睿智医药 根据公开资料，身为"90后"的高莹莹曾有8年的地方电视台主持人经验，此后方跨界至企业任职。 根据官网，睿智医药是一家全球领先的生物药、化学药一站式医药研发及生产服务提供商，致力于为全球制药企业、生物技术公司及科研院校提供 从早期发现到规模化生产的全生命周期一体化解决方案。然而，纵观高莹莹的履历，其中并无医药领域任职经验，也没有资本市场相关的任职经 验，因此部分股民对高莹莹的此番任职表示质疑。 不过，根据睿智医药12月1日的公告，高莹莹已取得深圳证券交易所颁发的《上市公司董事会秘书培训证明》，具备任职所需的工作经验和专业知 识，其任职资格符合《公司法》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 ...

Core Insights - Beijing Zheyuan Technology Co., Ltd. announced the completion of A1 round financing amounting to 1 billion yuan [1] - The financing was led by Guokai Investment, with participation from Zeyuan Fund and Ruizhi Pharmaceutical [1] - The funds will be primarily used for advancing the core drug pipeline, global patent layout for high-value innovative IP, and upgrading the computational medicine platform [1] Company Developments - Zheyuan Technology is accelerating the development of multiple drug pipelines targeting complex diseases [1] - The company is focusing on self-developed drug pipelines for diseases such as pancreatic cancer, central nervous system tumors, chordoma, and liver cancer [1]

Core Viewpoint - The rapid resignation of Gao Yingying as the board secretary of Ruizhi Pharmaceutical raises questions about the company's management stability and the qualifications of its leadership [1][3][5]. Group 1: Management Changes - Gao Yingying applied for resignation from her position as board secretary just 11 days after her appointment, which was effective immediately upon delivery to the board [1][3]. - Her predecessor, Xu Jian, resigned on December 1, citing work adjustment as the reason for his early departure [3]. - The company has not provided further details regarding the reasons for Gao's quick departure, and inquiries from media have gone unanswered [5]. Group 2: Background of Gao Yingying - Gao Yingying, born in 1994, has a background as a television host with 8 years of experience before transitioning to corporate roles [6][8]. - She has held positions in various broadcasting companies and recently served as a promotion director at Zhongshan Anxin New Retail Company before joining Ruizhi Pharmaceutical [8]. - Despite her lack of experience in the pharmaceutical industry and capital markets, she has obtained the necessary qualifications to serve as board secretary, including a training certificate from the Shenzhen Stock Exchange [8]. Group 3: Compensation - The previous board secretary, Xu Jian, had a total pre-tax remuneration of 1.508 million yuan for 2024, with previous years' salaries being 1.67 million yuan in 2022 and 1.4443 million yuan in 2023 [9].

证券日报网讯12月15日，睿智医药（300149）在互动平台回答投资者提问时表示，截至2025年12月10日 公司的股东人数为39313户。 ...

智通财经记者 | 李科文 智通财经编辑 | 谢欣 12月12日晚间，睿智医药公告，公司董事会秘书高莹莹因工作职务调整，申请辞去董事会秘书职务，辞职报告自送达董事会之 日起生效。 值得注意的是，自就任睿智医药董事会秘书至辞职，高莹莹任职时间仅为11天。高莹莹此前并无上市公司董秘从业经历，职业 背景主要来自地方广播电视系统。 据履历信息，2016年7月至2020年3月，高莹莹在阳江广播电视台任策划、主持人、编导、编辑；2020年3月至2022年9月，在中 山广播电视台担任主持人、栏目策划及编导。其间，她曾与双胞胎姐姐高晶晶共同主持《晶莹睇透》《晶莹宝贝》《文学悦 听》《水上冲关》等节目。 12月15日，智通财经致电睿智医药董秘办，询问高莹莹离任是否与近期网络舆情有关。睿智医药投资者关系相关工作人员向智 通财经回应称，相关变动原因以公告披露内容为准。 睿智医药是国内较早成立的合同研究组织（CRO）公司。其前身睿智化学成立于2003年，在行业起步阶段，一度与如今的A股 医药合同研发生产组织（CDMO）龙头药明康德平齐。 胡瑞连曾是睿智化学的财务投资者。2017年5月，胡瑞连控制的Mega Star受让睿智化学23.5 ...

Core Viewpoint - Recently, Ruizhi Pharmaceutical (SZ300149) announced the resignation of its Secretary of the Board, Gao Yingying, due to job adjustments, which raises questions about management stability and continuity within the company [1][3]. Group 1: Management Changes - Gao Yingying, born in 1994, submitted her resignation just 11 days after taking office as Secretary of the Board, which is a notably short tenure [3]. - Gao was originally appointed to serve until the end of the sixth Board term and did not hold any shares in the company at the time of her resignation [3]. - The company has appointed the Chairman and CEO, Woosweelian, to temporarily assume the duties of the Secretary of the Board while a new appointment is made [3]. Group 2: Background of Gao Yingying - Gao Yingying holds a bachelor's degree and is currently pursuing a Master's in Business Administration at Shanghai Normal University [3]. - Prior to joining Ruizhi Pharmaceutical, she worked in various roles at local broadcasting stations from 2016 to 2022, including planning, hosting, directing, and editing [3]. - In November 2022, she transitioned to Zhongshan Anxin New Retail Co., Ltd. as Promotion Director before officially becoming the Secretary of the Board at Ruizhi Pharmaceutical in December 2025 [3]. Group 3: Company Overview - Ruizhi Pharmaceutical is a provider of integrated research and production services for biopharmaceuticals and chemical drugs, aiming to offer comprehensive lifecycle solutions from early discovery to large-scale production for global pharmaceutical companies, biotechnology firms, and research institutions [3].

Group 1 - The company announced the resignation of its board secretary, Gao Yingying, who had held the position for less than two weeks after being appointed on December 1, 2025 [1][2] - Gao Yingying was noted to have the necessary qualifications and experience for the role, having obtained the required training certification from the Shenzhen Stock Exchange [2] - The company has appointed its chairman and CEO, Woo Swee Lian, to act as the board secretary until a new appointment is made [3] Group 2 - Gao Yingying's previous experience includes roles in broadcasting and as a promotion director at a retail company before joining the firm [3] - The company has experienced significant fluctuations in its financial performance, with net profits of -1.55 billion, 4.02 billion, 3.63 billion, -9.17 billion, and -2.26 billion from 2020 to 2024, totaling over 1 billion in losses [3] - In the first three quarters of 2025, the company reported revenue of 8.17 billion, a year-on-year increase of 13.68%, and a net profit of 709.13 million, up 111.5% [3] Group 3 - As of December 12, 2025, the company's stock price was 9.82 CNY per share, with a total market capitalization of 4.89 billion [4][5]

来源：小王谈财经 来源：小王谈财经 ...

每经头条（nbdtoutiao）——实施城乡居民增收计划、降准降息等工具灵活高效运用、增加普通高中学 位……深度解读中央经济工作会议 （记者 曾健辉） 截至发稿，睿智医药市值为49亿元。 每经AI快讯，睿智医药（SZ 300149，收盘价：9.82元）12月12日晚间发布公告称，睿智医药科技股份 有限公司董事会秘书高莹莹女士因工作职务调整，申请辞去公司董事会秘书职务。 2025年1至6月份，睿智医药的营业收入构成为：医药研发服务及生产外包占比99.06%，益生元系列占 比0.52%，租金收入占比0.35%，其他行业占比0.07%。 ...